Quantcast

Latest Multiple Myeloma Research Foundation Stories

2009-01-26 10:00:00

FJC, a foundation of philanthropic donor-advised funds and the Myeloma Research Foundation are the latest major donors to the "Cure Myeloma Project", an ongoing research initiative at the Institute for Myeloma and Bone Cancer Research, (IMBCR), in Los Angeles, CA LOS ANGELES, Jan.

2008-11-06 15:00:28

The International Myeloma Foundation (IMF)--supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians--today called for all patients to have access to the newest pharmaceuticals making life-changing advances in the treatment of myeloma.

2008-10-23 15:00:28

Certain genes can influence a person's likelihood to contract and recover from a particular disease such as cancer, U.S. researchers said.

2008-10-17 09:00:27

Celgene and Acceleron Pharma have initiated a Phase II clinical study of its lead compound ACE-011 in patients with multiple myeloma. Celgene will make a $5 million milestone payment to Acceleron in accordance with the terms of the collaboration agreement between the two companies.

2008-10-16 09:00:10

Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the initiation of a Phase 2 clinical study of its lead compound ACE-011 in patients with multiple myeloma.

2008-10-14 09:00:44

The Multiple Myeloma Research Consortium has initiated a three-drug combination study of elotuzumab, a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with Revlimid, and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse.

2008-10-13 12:00:41

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a three-drug combination study of elotuzumab (also known as HuLuc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with REVLIMID(R) (lenalidomide), and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse.

2008-09-29 09:00:57

The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy, and support for myeloma patients, families, researchers, and physicians - today heralded the expansion of treatment options for previously untreated patients with multiple myeloma, giving patients in Canada and Europe access to drugs similar to what is available to patients in the United States.

2008-08-25 12:01:19

The Multiple Myeloma Research Consortium has started a Phase I/II clinical trial with the oral immunomodulatory agent pomalidomide in patients who have received at least two prior therapies including treatments with Revlimid and Velcade for injection.


Word of the Day
ecotone
  • A transitional zone between two communities containing the characteristic species of each.
The word 'ecotone' comes 'eco-' plus a Greek root meaning 'tension'.